The Food and Drug Administration says that the manufacturers of these blockbuster products, commonly used to treat rheumatoid arthritis and other serious illnesses, must strengthen the existing warnings in their prescribing information and medication guides, adding cautions on the risk of developing opportunistic fungal infections.
Read the full article here
